This proposal for a Cancer Center Support Grant (CCSG) requests funding to support the cancer research activities of the Kimmel Cancer Center (KCC) in order to increase the survival and quality of life of cancer patients by translating basic research discoveries into new strategies to prevent, diagnose, monitor and cure human cancer. The major thrust of the Kimmel Cancer Center is in discovery and translation of discoveries in the genetics, cell biology, biochemistry and immunology of cancer into novel modalities to cure cancer. The Kimmel Cancer Center consists of seven Programs and fifteen Shared Resources to support the research programs. Investigators in each Program are involved in intraprogrammatic and interprogrammatic collaborations and have been extremely successful in obtaining peer reviewed funding for these collaborative studies. The collaborative environment within the KCC has facilitated numerous collaborative studies and publications that have contributed to important advances in cancer research. The KCC Programs are supported by $30 million in annual direct costs from NCI approved peer reviewed funding with $18 million of that funding coming from 95 NCI sponsored projects, including eight interprogrammatic NCI program project grants. The efforts of the Director and his recruits have resulted in a considerable increase in philanthropic and University support, NCI funding, and in the decision by Thomas Jefferson University to build a new KCC facility of approximately 500,000 square feet that will accommodate the basic, clinical and translational efforts of the KCC investigators. This new KCC facility will enhance even further the translational cancer research effort of the Kimmel Cancer Center.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Center Core Grants (P30)
Project #
3P30CA056036-08S1
Application #
7276820
Study Section
Subcommittee G - Education (NCI)
Program Officer
Shafik, Hasnaa
Project Start
1995-06-22
Project End
2008-05-31
Budget Start
2005-06-01
Budget End
2008-05-31
Support Year
8
Fiscal Year
2006
Total Cost
$4,440,350
Indirect Cost
Name
Thomas Jefferson University
Department
Internal Medicine/Medicine
Type
Schools of Medicine
DUNS #
053284659
City
Philadelphia
State
PA
Country
United States
Zip Code
19107
McNair, Christopher; Xu, Kexin; Mandigo, Amy C et al. (2018) Differential impact of RB status on E2F1 reprogramming in human cancer. J Clin Invest 128:341-358
Garcia, Samantha A; Lebrun, Aurore; Kean, Rhonda B et al. (2018) Clearance of attenuated rabies virus from brain tissues is required for long-term protection against CNS challenge with a pathogenic variant. J Neurovirol 24:606-615
Vido, Michael J; Le, Kaitlyn; Hartsough, Edward J et al. (2018) BRAF Splice Variant Resistance to RAF Inhibitor Requires Enhanced MEK Association. Cell Rep 25:1501-1510.e3
Brody, Jonathan R; Dixon, Dan A (2018) Complex HuR function in pancreatic cancer cells. Wiley Interdiscip Rev RNA 9:e1469
Liao, Lili; Liu, Zongzhi Z; Langbein, Lauren et al. (2018) Multiple tumor suppressors regulate a HIF-dependent negative feedback loop via ISGF3 in human clear cell renal cancer. Elife 7:
Heeke, Arielle L; Pishvaian, Michael J; Lynce, Filipa et al. (2018) Prevalence of Homologous Recombination-Related Gene Mutations Across Multiple Cancer Types. JCO Precis Oncol 2018:
Parent, Kristin N; Schrad, Jason R; Cingolani, Gino (2018) Breaking Symmetry in Viral Icosahedral Capsids as Seen through the Lenses of X-ray Crystallography and Cryo-Electron Microscopy. Viruses 10:
Rappaport, Jeffrey A; Waldman, Scott A (2018) The Guanylate Cyclase C-cGMP Signaling Axis Opposes Intestinal Epithelial Injury and Neoplasia. Front Oncol 8:299
Pandya, Kalgi D; Palomo-Caturla, Isabel; Walker, Justin A et al. (2018) An Unmutated IgM Response to the Vi Polysaccharide of Salmonella Typhi Contributes to Protective Immunity in a Murine Model of Typhoid. J Immunol 200:4078-4084
Hussain, Maha; Daignault-Newton, Stephanie; Twardowski, Przemyslaw W et al. (2018) Targeting Androgen Receptor and DNA Repair in Metastatic Castration-Resistant Prostate Cancer: Results From NCI 9012. J Clin Oncol 36:991-999

Showing the most recent 10 out of 807 publications